专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008135419A2 ANTI-IL-6-AGENTS FOR IMPROVING PRIMARY FUNCTIONING OF ALLOGENIC GRAFTS 审中-公开
标题翻译：用于改善原始植物的主要功能的抗IL-6代谢物
公开(公告)号：WO2008135419A2
公开(公告)日：2008-11-13
申请号：PCT/EP2008/055124
申请日：2008-04-25
申请人： CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN , SAWITZKI, Birgit , GONG, Weihua , PASCHER, Andreas , VOLK, Hans-Dieter
发明人： SAWITZKI, Birgit , GONG, Weihua , PASCHER, Andreas , VOLK, Hans-Dieter
IPC分类号： A61K38/20 , A61K39/395 , C07K16/24 , C07K16/28 , A61P37/06
CPC分类号： C07K16/2866 , A61K31/365 , A61K31/407 , A61K38/1774 , A61K2039/505 , C07K2317/76
摘要： The present invention relates to the use of interleukin-6 antagonists for preventing, treating or ameliorating delayed graft function and/or for improving primary and/or long term graft function, particularly in kidney transplantation, and corresponding medicaments.
摘要翻译：本发明涉及白细胞介素-6拮抗剂用于预防，治疗或改善延迟移植物功能和/或用于改善初级和/或长期移植功能，特别是在肾移植中以及相应药物的用途。

2. 发明申请

WO2008089832A1 METHOD FOR RISK PREDICTION OF A POSTOPERATIVE SEPSIS IN A HUMAN 审中-公开
标题翻译：风险预测在人类中的术后性行为的方法
公开(公告)号：WO2008089832A1
公开(公告)日：2008-07-31
申请号：PCT/EP2007/011207
申请日：2007-12-19
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN , KOTSCH, Katja , VOLK, Hans-Dieter , KEH, Didier
发明人： KOTSCH, Katja , VOLK, Hans-Dieter , KEH, Didier
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/6863 , C12Q1/6883 , C12Q2600/158 , G01N2333/525 , G01N2333/70596 , G01N2333/715 , G01N2800/26
摘要： The present invention generally relates to the field of diagnosis, and in particular to a method suitable to predict the risk of a postoperative sepsis in a human. The present invention further relates to a diagnostic kit for the risk prediction of a postoperative sepsis in a human.
摘要翻译：本发明一般涉及诊断领域，特别涉及一种适合于预测人类手术后败血症风险的方法。本发明还涉及用于人类术后败血症风险预测的诊断试剂盒。

3. 发明申请

WO2011107595A1 HIGH THROUGHPUT ANALYSIS OF T-CELL RECEPTOR REPERTOIRES 审中-公开
标题翻译： T细胞受体代谢物的高通量分析
公开(公告)号：WO2011107595A1
公开(公告)日：2011-09-09
申请号：PCT/EP2011/053314
申请日：2011-03-04
申请人： CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN , REINKE, Petra , VOLK, Hans-Dieter , BABEL, Nina
发明人： REINKE, Petra , VOLK, Hans-Dieter , BABEL, Nina
IPC分类号： G01N33/50
CPC分类号： G01N33/5308 , Y02A50/58
摘要： A method for analysis of a T cell repertoire is provided, whereby T cell receptor protein sequences are obtained from lymphocytes, TCR sequences are aligned with a TCR sequence data base, and TCR sequences aligning to data base sequences are selected and their frequency distribution is determined. The TCR sequence data base is obtained by stimulating lymphocytes in vitro with antigens, selecting T cells responding to stimulation and obtaining TCR sequences from the selected cells, or comprises TCR specific for a tumour or an adoptively transferred T cell. Additionally, a method to obtain antigen-specific T cells for adoptive transfer is provided, whereby T cells responding to stimulation with antigens are selected, T cells comprising certain TCR sequences are obtained by culturing individual clones or by transferring a transgenic TCR into a T cell.
摘要翻译：提供了一种分析T细胞谱的方法，由此从淋巴细胞获得T细胞受体蛋白序列，TCR序列与TCR序列数据库进行比对，并选择与数据碱基序列相对应的TCR序列，并确定其频率分布。通过用抗原体外刺激淋巴细胞来获得TCR序列数据库，选择响应于刺激的T细胞并从所选择的细胞获得TCR序列，或包含对肿瘤或过继转移的T细胞特异的TCR。另外，提供了用于获得用于过继转移的抗原特异性T细胞的方法，由此选择响应于用抗原刺激的T细胞，通过培养单个克隆或通过将转基因TCR转移到T细胞中获得包含某些TCR序列的T细胞。

4. 发明申请

WO2007128482A1 USE OF A B-CELL-DEPLETING ANTIBODY FOR TREATMENT OF POLYOMA VIRUS INFECTIONS 审中-公开
标题翻译：使用B细胞去除抗体治疗多瘤病毒感染
公开(公告)号：WO2007128482A1
公开(公告)日：2007-11-15
申请号：PCT/EP2007/003878
申请日：2007-05-02
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN , REINKE, Petra , VOLK, Hans-Dieter , HAMMER, Markus , BABEL, Nina , BOLD, Gana
发明人： REINKE, Petra , VOLK, Hans-Dieter , HAMMER, Markus , BABEL, Nina , BOLD, Gana
IPC分类号： A61K39/395 , A61P31/20 , A61K31/675 , A61P13/12 , A61P37/06 , C07K16/28
CPC分类号： C07K16/2887 , A61K2039/505 , C07K2317/24
摘要： The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection.
摘要翻译：本发明涉及B细胞消耗性抗体用于治疗多瘤病毒感染的用途。

5. 发明申请

WO2011138609A1 METHOD OF DETERMINING KIDNEY TRANSPLANTATION TOLERANCE 审中-公开
标题翻译：确定KIDNEY移植耐力的方法
公开(公告)号：WO2011138609A1
公开(公告)日：2011-11-10
申请号：PCT/GB2011/050874
申请日：2011-05-04
申请人： KING'S COLLEGE LONDON , CHARITÉ - UNIVERITÄTSMEDIZIN BERLIN , MILTENYI BIOTEC GMBH , HERNANDEZ-FUENTES, Maria , MESA, Irene , JANSSEN, Uwe , TOMIUK, Stefan , SAWITZKI, Birgit , VOLK, Hans-Dieter , LECHLER, Robert
发明人： HERNANDEZ-FUENTES, Maria , MESA, Irene , JANSSEN, Uwe , TOMIUK, Stefan , SAWITZKI, Birgit , VOLK, Hans-Dieter , LECHLER, Robert
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6876 , C12Q1/6837 , C12Q1/6883 , C12Q2600/158
摘要： The present invention relates to a method of determining an individual's transplantation tolerance by determining the level of a number of biomarkers. The present invention also relates to a kit comprising reagents for detecting the levels of the biomarkers. The present invention also relates to a sensor for detecting the expression levels of a plurality of genes that can be used to determine an individual's transplantation tolerance.
摘要翻译：本发明涉及通过确定多个生物标志物的水平来确定个体的移植耐受性的方法。本发明还涉及包含用于检测生物标志物水平的试剂的试剂盒。本发明还涉及用于检测可用于确定个体移植耐受性的多种基因的表达水平的传感器。

6. 发明申请

WO2004018504A2 IMMUNMARKER ZUR DIAGNOSTIK UND THERAPIE IM ZUSAMMENHANG MIT TRANSPLANTAT-REAKTIONEN 审中-公开
标题翻译： IMMUNOMARKERS诊断和治疗与移植反应有关
公开(公告)号：WO2004018504A2
公开(公告)日：2004-03-04
申请号：PCT/EP2003/009355
申请日：2003-08-22
申请人： CHARITE-UNIVERSITÄTS MEDIZIN BERLIN , SAWITZKI, Birgit , VOLK, Hans-Dieter , WOOD, Kathryn , LEHMANN, Manfred
发明人： SAWITZKI, Birgit , VOLK, Hans-Dieter , WOOD, Kathryn , LEHMANN, Manfred
IPC分类号： C07K14/00
CPC分类号： C12Q1/6883 , C12Q1/6881 , C12Q2600/158
摘要： Die Erfindung betrifft Immunmarker zur Detektion von Entzündungen, Immunreaktionen und insbesondere von Transplantattoleranzen bzw. Transplantat-Reaktionen, ein Verfahren zur Detektion von Transplantat-Reaktionen oder -toleranzen sowie die Verwendung von Immunmarkern zur medizinischen Prophylaxe, klinischen Verlaufskontrolle, Transplantat-Nachbehandlung, der klinischen Diagnostik und/oder der Therapie im Zusammenhang mit Zell-, Gewebe- bzw. Organtransplantationen.
摘要翻译：
本发明涉及一种用于检测炎性导航用途发明，免疫应答的免疫标记，特别是接枝公差或接枝反应，用于检测移植物反应或公差的方法，以及使用用于医疗预防免疫标记的，临床随访，移植随访，与细胞，组织或器官移植相关的临床诊断和/或治疗。

7. 发明申请

WO2018219959A1 CD8 T CELL SUBSETS AS A BIOMARKER FOR PREDICTING NON-FUSION AFTER SPINAL FUSION SURGERY 审中-公开
公开(公告)号：WO2018219959A1
公开(公告)日：2018-12-06
申请号：PCT/EP2018/064085
申请日：2018-05-29
申请人： CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
发明人： REINKE, Simon , GEIßLER, Sven , DUDA, Georg , VOLK, Hans-Dieter , FUCHS, Michael , SCHMIDT-BLEEK, Katharina , STRUBE, Patrick , PUMBERGER, Matthias
IPC分类号： G01N33/569 , A61K38/00
摘要： The present invention relates to a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28- and CD8+CD57+CD28- in a sample obtained from a patient. The invention further relates to a system for predicting the probability of having or developing a non-fusion.

8. 发明申请

WO2022136551A1 REPROGRAMMING IMMUNE CELLS BY TARGETED INTEGRATION OF ZETA-DEFICIENT CHIMERIC ANTIGEN RECEPTOR TRANSGENES 审中-公开
公开(公告)号：WO2022136551A1
公开(公告)日：2022-06-30
申请号：PCT/EP2021/087306
申请日：2021-12-22
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： KATH, Jonas Christian , REINKE, Petra , SCHMÜCK-HENNERESSE, Michael , VOLK, Hans-Dieter , WAGNER, Dimitrios Laurin
IPC分类号： C07K14/725 , C12N9/22 , A61K35/17 , A61P35/00 , C12N5/0783
摘要： The invention relates to a nucleic acid construct for targeting and integrating a CD3 zeta-deficient chimeric antigen receptor (CAR) fragment into an endogenous CD3 zeta/CD247 gene of a host genome. The invention further relates to a genetically modified human cell expressing an exogenous nucleic acid sequence encoding a CD3 zeta deficient CAR fragment, integrated in- frame into the endogenous CD3 zeta/CD247 gene for gene fusion, to form a functional CAR comprising an exogenous CAR fragment fused with an endogenous CD3 zeta domain.

9. 发明申请

WO2022034233A1 IMMUNOSUPPRESSANT-RESISTANT T-CELLS FOR ADOPTIVE IMMUNOTHERAPY 审中-公开
公开(公告)号：WO2022034233A1
公开(公告)日：2022-02-17
申请号：PCT/EP2021/072651
申请日：2021-08-13
申请人： CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN
发明人： AMINI, Leila , SCHMÜCK-HENNERESSE, Michael , REINKE, Petra , VOLK, Hans-Dieter , WAGNER, Dimitrios Laurin
IPC分类号： C12N5/0783 , A61P31/12 , A61P35/00 , C12N9/22 , C12N15/85
摘要： The present invention provides to the field of cell therapy, in particular, to adoptive T cell or NK cell therapy. It provides a human immunophilin knockout cell that is a T cell or NK cell, wherein the immunophilin is FKBP12 or cyclophilin A, or a cell population of such cells. The cell is resistant to the action of the immunosuppressant Tacrolimus and/or cyclosporine A. It is obtainable by CRISPR/Cas, e.g., CRISPR/Cas9-mediated knockout of the immunophilin or a derivate technology. The cell can be, e.g., a virus-specific cell, e.g., specific for an antigen from any of CMV, EBV, BKV, HPV, ADV, influenza virus, or SARS-CoV-2. It may also be a regulatory T cell. The invention also provides a method for preparing the human immunophilin knockout T cell or NK cell of the invention, pharmaceutical compositions or kits comprising said cells, pharmaceutical compositions or kits for use in in treatment or prevention of an infection with a virus or another pathogen or for use in treatment of cancer, or for use in balancing an unwanted immune response, e.g., in the context of a condition selected from the group comprising autoimmunity, allergy, a transplantation and bystander activation. Methods of treatment are also disclosed.

10. 发明申请

WO2019043148A1 IMMUNMODULATION FOR PREVENTION OF POOR HEALING OF MUSCULOSKELETAL INJURIES IN COMPROMISED PATIENTS 审中-公开
公开(公告)号：WO2019043148A1
公开(公告)日：2019-03-07
申请号：PCT/EP2018/073453
申请日：2018-08-31
申请人： CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN
发明人： SCHMIDT-BLEEK, Katharina , VOLK, Hans-Dieter , WENDLER, Sebastian , DUDA, Georg N. , REINKE, Simon , GEISSLER, Sven , QAZI, Talmoor Hasan , DIENELT, Anke , SCHELL, Hanna
IPC分类号： A61K45/00 , A61P19/00
摘要： The present invention relates to a compound for use in a method for treating a musculoskeletal injury, wherein the compound is a regulator of the pro-inflammatory response and particularly being capable of upregulating regulatory T cells and/or M2- macrophages; and/or being capable of downregulating the biological activity of effector CD8+ cells, and further comprising the dosage regimen administering an initial dose of said compound to a patient not before 24 hours after said musculoskeletal injury.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式